Granted Patent B2

US 12,398,094 · App. 18/203,678 · Granted Aug 26, 2025

Inventors: Michael Paul Cruskie, Jr. (Florence, SC); Joshua Kyle Bolger (Florence, SC); Jonathan Blake Mckenzie (Latta, SC); Pratik Sheth (North Grafton, MA); Richard Edwards (Cambridge, GB); Alex Eberlin (Cambridge, GB); Michael Markey (Northborough, MA)

Assignee: RADIUS PHARMACEUTICALS, INC.

C07C217/84A61P35/00C07C213/10C07B2200/13

Abstract

Claims (23)

1. A solid form of RAD1901-2HCl,

wherein the solid form of RAD1901-HCl is a mixture of solid Form 2 and solid Form 3 of RAD1901-2HCl, and is characterized by an X-Ray powder diffraction pattern comprising peaks, in terms of 2-theta, at 6.3 degrees 2θ±0.2 degree 20 and 12.5 degrees 2θ±0.2 degree 20 at relative humidity 0%, and further characterized by an X-Ray powder diffraction pattern comprising peaks, in terms of 2-theta, at 5.8 degrees 2θ±0.2 degree 2θ, 21.3 degrees 2θ±0.2 degree 2θ and 24.8 degrees 2θ±0.2 degree 2θ, at about relative humidity 92%.

2. The solid form of RAD1901-2HCl according to claim 1 , wherein the solid form is characterized by an X-ray powder diffraction pattern comprising peaks, in terms of 2-theta, at 6.3 degrees 2θ±0.2 degree 2θ, 12.5 degrees 2θ±0.2 degree 2θ, and 15.4 degrees 2θ±0.2 degree 2θ, at relative humidity 0%, and further characterized by an X-Ray powder diffraction pattern comprising peaks, in terms of 2-theta, at 5.8 degrees 2θ±0.2 degree 2θ, 21.3 degrees 2θ±0.2 degree 2θ, 23.3 degrees 2θ±0.2 degree 2θ, and 24.8 degrees 2θ±0.2 degree 2θ, at about relative humidity 92%.

3. The solid form of RAD1901-2HCl according to claim 2 , wherein the solid form is characterized by an X-ray powder diffraction pattern comprising peaks, in terms of 2-theta, at 6.3 degrees 2θ±0.2 degree 2θ, 12.5 degrees 2θ±0.2 degree 2θ, 13.4 degrees 2θ±0.2 degree 2θ, and 15.4 degrees 2θ±0.2 degree 2θ, at relative humidity 0%, and further characterized by an X-Ray powder diffraction pattern comprising a peak, in terms of 2-theta, at 5.8 degrees 2θ±0.2 degree 2θ, 12.1 degrees 2θ±0.2 degree 2θ, 21.3 degrees 2θ±0.2 degree 2θ, 23.3 degrees 2θ±0.2 degree 2θ, and 24.8 degrees 2θ±0.2 degree 2θ, at about relative humidity 92%.

4. The solid form of RAD1901-2HCl according to claim 3 , wherein the solid form is characterized by an X-ray powder diffraction pattern comprising peaks, in terms of 2-theta, at 6.3 degrees 2θ±0.2 degree 2θ, 12.5 degrees 2θ±0.2 degree 2θ, 13.4 degrees 2θ±0.2 degree 2θ, 15.4 degrees 2θ±0.2 degree 2θ, and 18.3 degrees 2θ±0.2 degree 2θ, at relative humidity 0%, and further characterized by an X-Ray powder diffraction pattern comprising a peak, in terms of 2-theta, at 5.8 degrees 2θ±0.2 degree 2θ, 9.5 degrees 2θ±0.2 degree 2θ, 12.1 degrees 2θ±0.2 degree 2θ, 21.3 degrees 2θ±0.2 degree 2θ, 23.3 degrees 2θ±0.2 degree 2θ, and 24.8 degrees 2θ±0.2 degree 2θ, at about relative humidity 92%.

5. The solid form of RAD1901-2HCl according to claim 1 , having a dynamic vapor sorption (DVS) isotherm plot collected from 0 to 90% relative humidity, as shown in FIG. 6 A .

6. The solid form of RAD1901-2HCl according to claim 1 , having a dynamic vapor sorption (DVS) kinetic plot collected from 0 to 90% relative humidity, as shown in FIG. 6 B .

7. A pharmaceutical composition comprising the solid form of RAD1901-2HCl according to claim 1 , and one or more pharmaceutically acceptable excipients.

8. A method of treating breast cancer or ovarian cancer, the method comprising administering to a subject in need thereof the solid form of RAD1901-2HCl according to claim 1 , or a pharmaceutical composition according to claim 7 .

9. The method according to claim 8 , wherein said breast cancer or ovarian cancer is ER+.

10. The method according to claim 9 , wherein the breast cancer or ovarian cancer is a resistant ER-driven cancer that progressed after endocrinological treatment, wherein the endocrinological treatment comprises administration of a drug selected from a Selective Estrogen Receptor Degrader (SERD), an aromatase inhibitor, a selective estrogen receptor modulator (SERM), a Human Epidermal Growth Factor Receptor 2 (Her2) inhibitor, a chemo therapeutic agent, a cdk4/6 inhibitor, an m-TOR inhibitor, an angiogenesis inhibitor, or rituximab.

11. The method according to claim 10 , wherein

the SERD is selected from fulvestrant, 17β-[2-[4-[(diethylamino)methyl]-2-methoxyphenoxy]ethyl]-7α-methylestra-1,3,5 (10)-trien-3-ol (TAS-108 or (SR16234), 11β-Fluoro-7α-(14,14,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl) estra-1,3,5 (10)-triene-3,17β-diol (ZK191703), (118,17β)-11-[4-[5-[(4,4,5,5,5-Pentafluoropentyl) sulfonyl]-pentyl]oxy]phenylestra-1,3,5, (10)-triene-3,17-diol (RU58668), Brilanestrant (GDC-0810 or (ARN-810), Etacstil (GW5638 or/DPC974), (S)-2-(4-(2-(3-(fluoromethyl)-azetidin-1-yl) ethoxy)phenyl)-3-(3-hydroxyphenyl)-4-methyl-2H-chromen-6-ol (SRN-927), and (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido [3,4-b]indol-1-yl)phenyl) acrylic acid (AZD9496);

the aromatase inhibitor is selected from anastrozole, exemestane, and letrozole;

the selective estrogen receptor modulator is selected from tamoxifen, raloxifene, lasofoxifene, and toremifene;

the Her2 inhibitor is selected from trastuzumab, lapatinib, ado-trastuzumab emtansine, and pertuzumab;

the chemo therapeutic agent is selected from abraxane, adriamycin, carboplatin, cytoxan, daunorubicin, doxil, ellence, fluorouracil, gemzar, helaven, lxempra, methotrexate, mitomycin, micoxantrone, navelbine, taxol, taxotere, thiotepa, vincristine, and xeloda; and

the angiogenesis inhibitor is bevacizumab.

12. The method according to claim 8 , wherein the subject is further administered a cdk4/6 inhibitor and/or an m-TOR inhibitor.

13. The method according to claim 12 , wherein the cdk4/6 inhibitor and/or m-TOR inhibitor is selected from palbociclib, ribociclib, abemaciclib, or everolimus, or a combination thereof.

14. The method according to claim 8 , wherein the breast cancer or ovarian cancer is a resistant ER-driven cancer that progress after endocrinological treatment, wherein the breast cancer has one or more mutant ER binding domains comprising one or more mutations selected from the group consisting of Y537X1 wherein X1 is S, N, or C, D538G, L536X2 wherein X2 is R or Q, P535H, V534E, S463P, V392I, and E380Q, or a combination thereof.

15. The method according to claim 8 , wherein the method comprises treating breast cancer.

16. The method according to claim 8 , wherein the method comprises treating ovarian cancer.

Assignments (1)

Continuity (6)

References Cited (400)